Ipsogen

Most random gene expression signatures are significantly associated with breast cancer outcome, according to a research team at Université Libre de Bruxelles.

Ipsogen's board has voted in favor of the deal, and shareholders holding 61 percent of Ipsogen's stock have agreed to sell their shares to Qiagen.

Qiagen's planned acquisition of Ipsogen will provide the firm with a suite of CE-IVD marked PCR tests as well as an Affymetrix-manufactured microarray test that can be used to guide treatment for breast cancer patients.

The acquisition will also bolster Qiagen's personalized medicine play through the addition of Ipsogen's extensive portfolio of personalized diagnostics and prognostics in the area of blood cancer.

Qiagen has entered into exclusive negotiations to acquire 47 percent of Ipsogen's stock. After the completion of that deal, Qiagen would move to acquire all remaining shares of the French cancer molecular diagnostic firm.

Sysmex will distribute certain Ipsogen products in Japan and submit Ipsogen products for the diagnosis and monitoring of BCR-ABL and JAK2 to Japanese health authorities.

Product Watch

Premium

Agilent's SureSelect XT Mouse All Exon kit; NanoString's nCounter Mouse miRNA Expression kit; Ipsogen's BCR-ABL Mbcr IS-MMR kits; ATCC's Universal Mycoplasma Detection kit.

New Releases

Premium

Ipsogen's BCR-ABL Mbcr

The Associated Press reports that gene-edited food may soon be for sale.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.